摘要
目的探讨99m锝-甲氧基异丁基异晴(technetium-99m methoxyisobutylisonitrile,99mTc-MIBI)脑显像预测高分级脑胶质瘤同步放化疗疗效的可能性。方法用SPECT/CT对67例高分级脑胶质瘤进行脑显像,于放化疗前肘静脉注射99mTc-MIBI 30 mCi,注射后30分钟和120分钟分别行早期相和延期相显像,计算肿瘤感兴趣区(region of interest,ROI)与对侧正常相应部位早期摄取比值(T/Ne)、延期摄取比值(T/Nd)和滞留率(RI%)。所有患者给予术后病灶三维适形放疗和替莫唑胺(temozolomide,TMZ)同步化疗,随后给予6个周期的TMZ辅助化疗。结果放化疗有效组49例(71.1%),中位生存期(MST)19月;无效组18例(28.9%),MST 11月,两者MST比较差异有统计学意义(P<0.05),前者T/Ne、T/Nd和RI%值为4.65±2.17、6.67±3.32及(16.11±2.35)%;后者为6.14±2.06、4.47±2.57及(5.40±2.61)%,T/Ne和T/Nd值比较差异无统计学意义(P>0.05),RI%值比较差异有统计学意义(P<0.05〉。结论99mTc-MIBI脑显像中RI%对高分级脑胶质瘤同步放化疗疗效有一定的预测作用。
Objective To investigate the role of technetium-99m methoxyisobutylisonitrile （99mTc-MIBI） imaging in predicting the response of concurrent radiochemotherapy in treatment of high grade glioma. Methods SPECT/CT brain scan was performed in patients with high grade glioma. Before treatment, 30 mCi 99mTc-MIBI was administered via ulnar vein. Early phase and delayed phase images were taken 30 rain and 120 rain after administration, respectively. T/Ne, T/Nd and RI% were calculated and compared between region of interest （ ROI ） and normal counterparts. All postoperative patients were treated with concurrent 3 dimension conformal radiotherapy and temozolomide （TMZ） chemotherapy followed by 6 months of TMZ chemotherapy alone. Results The median survival times of 49 （71.1% ） responsive patients and 18（28.9%） unresponsive patients were significantly different（ 19 months vs 11 months,P 〈 0.05）. The T/Ne,T/Nd and RI% of both groups were 4.65 ±2.17 vs 6.14± 2.06,6.67± 3.32 vs 4.47±2.57, （16.11 ± 2.35）% vs （5.40 ±2.61 ）% ,respectively. The differences in T/Ne and T/Nd were not significant （P 〉 0.05 ）,while the difference in RI% was statisitically significant （ P 〈 0.05 ）. Conclusion RI% of 99mTc-MIBI is a potential predictor of the response of concurrent chemoradiotherapy in treatment of high grade glioma.
出处
《实用肿瘤杂志》
CAS
2014年第1期77-79,共3页
Journal of Practical Oncology
